Acton, Mass.-based Cognoptix (formerly Neuroptix) has developed an entirely novel, early-stage diagnostic for Alzheimer’s disease (AD) to allow treatment before significant neuronal loss and irreversible brain damage occurs.
DARA Biosciences has created some buzz as of late, landing on several ‘watch lists’ after the company’s exclusive licensing of three market-ready products for distribution in the United States. CEO/Chief Medical Officer Dr. David Drutz and COO Chris Clement conducted a two-part interview with OneMedRadio discussing developmental milestones and key catalysts for Q4-2012 and 2013.
This is Part I of our special report on the state of immunotherapy in the public markets. This report looks at promising anticancer immunotherapy technologies, and the major issues in bringing these technologies to the general public.
Crystal Research Associates, LLC, an independent equity research firm, announced today a partnership with OneMedPlace to broaden services and provide additional visibility to research clients via the integrated OneMedPlace platform.
As Ryan Starkes, Partner and a Practice Leader within BDO’s Technology and Life Sciences Industry Group informs us, BDO is interested in emerging growth life science companies particularly those planning on exploring international development. All companies looking to utilize the capital markets in the U.S., including those in the life sciences industry, have always had to navigate particularly perplexing regulatory requirements.
There is no excerpt because this is a protected post.
There is no excerpt because this is a protected post.
2B Blackbio, dedicated to developing and marketing new solutions for personalized medicine, has obtained CE Marking for BlackLight Fungal ID Kit, intended for a fast and easy‐to‐use diagnostic test, allowing rapid identification of fungal infections.
Burrill & Company recently announced that Dr. Dirk Lammerts has been appointed as Managing Director of Digital Health.
Patients who dread traditional blood tests (and the accompanying needles) may one day have reason to rejoice. San Diego device company TearLab is developing a point-of-care diagnostic test that uses tears to identify disease-indicating protein biomarkers.
Copyright © 2024 | WordPress Theme by MH Themes